Patent Access& Intellectual property& FDA Regulations

A patent is an arrangement of select rights conceded by a sovereign state to an innovator or appointee for a constrained timeframe in return for point by point open divulgence of a creation. An innovation is an answer for a particular mechanical issue and is an item or a procedure. Licenses are a type of protected innovation. Regulatory affairs  is a comparatively new profession which developed from the desire of governments to protect public health by controlling the safety and efficacy of products in areas including pharmaceuticals, veterinary medicines, medical devices, pesticides, agrochemicals, cosmetics and complementary medicines. Regulatory Affairs  is involved in the development of new medicinal products from early on, by integrating regulatory principles and by preparing and submitting the relevant regulatory dossiers to health authorities.

  • Lifecycle management of drug products
  • Patents and disputes case studies
  • Identification techniques adulterated and misbranded drugs
  • FDCA (Federal Food, Drug, and Cosmetic Act )
  • Exemption in prescription and OTC drugs
  • Environmental health hazards

Related Conference of Patent Access& Intellectual property& FDA Regulations

August 20-21, 2018

12th Asian Biologics and Biosimilars Congress

Tokyo, Japan
August 29-30, 2018 |

International Conference and Exhibition on Drug Safety & Pharmacovigilance

Park Inn By Radisson, Toronto, Canada
October 18-20, 2018

18th World Pharma Congress

Warsaw, Poland
November 14-15, 2018

13th International Conference on Biosimilars and Biologics

Lisbon, Portugal
September 18-19, 2018

6 th European Biopharma Congress

Amsterdam, Netherlands

Patent Access& Intellectual property& FDA Regulations Conference Speakers

Recommended Sessions

Related Journals

Are you interested in